Following a weak Q4 FY25 results, shares of Neuland Laboratories fell as much as 11% on May 16, 2025. The company reported a 59% year-on-year decline in net profit and a 15% drop in revenue for the March quarter. Despite the downturn, Neuland Labs affirmed that its growth trajectory is expected to resume in FY26, with continued visibility on both short- and long-term opportunities.
Neuland reported a full-year decline in topline revenue and a contraction in operating margins, aligning with prior expectations.
Also Read: Tata Motors, Tata Steel: Which Tata Group Company Delivered Highest Growth in Q4FY25 Earnings?
The company expects a rebound in FY26, driven by capacity expansion and new molecule launches.
On May 16, 2025, shares of Neuland Laboratories (NSE: NEULANDLAB) opened at ₹11,050, lower than its previous close at ₹11,859. At 4 PM, the share price of Neuland Laboratories was trading at ₹11,040, down by 6.91% on the NSE.
While Neuland Laboratories faces short-term headwinds, including reduced profitability and revenue, the company’s strategic investments and product pipeline suggest a promising FY26. Analysts remain optimistic about its long-term growth potential, supported by strong fundamentals and expansion plans.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: May 16, 2025, 5:10 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates